Pharmafile Logo
Pharmafocus logo
Advanced Search

Venclyxto

Showing 7 posts of 7 posts found.

Venclyxto combo scores European approval for previously untreated chronic lymphocytic leukaemia

March 13, 2020
Medical Communications, Sales and Marketing AbbVie, European Commission, Roche, Venclyxto, pharma

The European Commission has moved to authorise AbbVie and Roche’s B-cell lymphoma-2 (BCL-2) inhibitor Venclyxto (venetoclax) when used in combination …

News
abbvie_0

AbbVie’s Venclyxto pins down CHMP approval for treatment-naive chronic lymphocytic leukaemia

February 3, 2020
Sales and Marketing AbbVie, CHMP, EMA, Venclyxto, pharma

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has awarded recommendation to AbbVie’s Venclyxto (venetoclax), …

News
abbvie_0

AbbVie’s Venclyxto combo outclasses chemo in treatment-naive chronic lymphocytic leukaemia

June 5, 2019
Research and Development ASCO 2019, AbbVie, Venclyxto, pharma

AbbVie was one of many companies to present new data at this year’s American Society of Clinical Oncology (ASCO) Annual …

News

Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE

January 18, 2019
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma

A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …

News
abbvie_0

AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma

AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …

News
acute_leukemia-all

Roche and AbbVie’s leukaemia combo smashes Phase 3 endpoint

September 19, 2017
Manufacturing and Production, Research and Development AbbVie, Rituxan, Roche, Venclexta, Venclyxto, leukaemia, pharma, pharmaceutical

Venclexta/Venclyxto (venetoclax), Roche and AbbVie’s oral B-cell lymphoma-2 (BCL-2) inhibitor, successfully met its primary endpoint in Phase 3 trials, providing …

News
abbvie_0

European thumbs up for Abbvie leukaemia drug

December 8, 2016
Medical Communications, Sales and Marketing AbbVie, Venclyxto

Abbvie has confirmed its Venclyxto (venetoclax) has been granted marketing authorisation by the European Commission (EC) as a monotherapy for …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023